All Healthcare Assets
62 assets analyzed by CleaRank Financial AI. Updated and expanding daily.
Healthcare combines pharmaceuticals, biotech, medical devices, and health services - a defensive sector with growth pockets in obesity therapeutics, oncology, and aging demographics. The space has earned premium valuations through 2025-2026 thanks to GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro) and accelerated FDA approval cycles for cell and gene therapies.
CleaRank tracks the largest pharma, biotech, and device makers with daily-refreshed valuations and trade plans. Healthcare typically displays lower beta than the broader market - making it a portfolio anchor - but binary FDA outcomes and patent cliffs can produce outsized single-name moves. Browse below to compare drug-developer pipelines, device innovators, and large-cap pharma dividend payers.
Frequently Asked Questions
Which healthcare stocks are most-watched right now?
Eli Lilly (LLY), Novo Nordisk, Johnson & Johnson (JNJ), Pfizer (PFE), and AbbVie (ABBV) sit at the top of analyst coverage. LLY in particular has dominated 2024-2026 trading thanks to its Mounjaro and Zepbound franchises.
Is the healthcare sector good for dividend investors?
Yes - large-cap pharma names (JNJ, PFE, MRK, ABBV) have historically delivered 2-4% dividend yields with consistent payout growth. Healthcare device makers (MDT, ABT) also pay dividends, though typically lower yields with stronger growth profiles.
What healthcare ETFs offer broad exposure?
XLV (Healthcare Select Sector SPDR) and VHT (Vanguard Health Care) are the largest. For sub-sector targeting: IBB (biotech), XBI (biotech equal-weight), IHI (medical devices), and XPH (pharmaceuticals).
How do FDA decisions impact healthcare stock prices?
Binary FDA outcomes can move clinical-stage biotech stocks 30-70% in a single session. Large-cap pharma names see smaller but still material moves (5-15%) on key drug approvals or rejections. The PDUFA calendar is the most-watched event-driven catalyst in the sector.
What are the biggest risk drivers for healthcare stocks?
Drug-pricing legislation, patent cliffs, and binary clinical-trial readouts are the sector's dominant risks. A failed Phase 3 trial can erase most of a clinical-stage biotech's value overnight, while patent expirations pressure large-cap pharma revenue for years. Reimbursement changes from Medicare drug-price negotiation add a policy layer that simple valuation screens often miss.